Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetics of nirmatrelvir/ritonavir and the drug-drug interaction with calcineurin inhibitor in renal transplant recipients.

European journal of clinical pharmacology - 1 Aug 2024

Xu Xueyin, Zhang Huanxi, Liu Longshan, Fu Qian, Wu Chenglin, Lin Xiaobin, Tang Kejing, Wang Changxi, Chen Pan

Abstract excerpt

OBJECTIVES: To describe the pharmacokinetic (PK) characteristics of nirmatrelvir/ritonavir in renal transplant recipients and explore the potential factors that related to the PK variance of nirmatrelvir/ritonavir and its interaction with calcineurin inhibitor (CNI). METHODS: Renal transplant recipients treated with CNI and nirmatrelvir/ritonavir were prospectively enrolled. Steady-state plasma concentrations of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Calcineurin Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to Drug Interactions

Share to Immunosuppressive Agents

Share to Ritonavir

Share to Tacrolimus

Share to Transplant Recipients

Source

Identifiers

PMID: 38691139
DOI: 10.1007/s00228-024-03691-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetics of nirmatrelvir/ritonavir and the drug-drug interaction with calcineurin inhibitor in renal transplant recipients.PMID 38691139Read ↗

Molnupiravir as a Safer Alternative to Nirmatrelvir/Ritonavir in Kidney and Pancreas-Kidney Transplant Recipients Receiving Tacrolimus: A Single-Center Retrospective AnalysisSemantic proximity Read ↗

Effects of Postoperative Day and NR1I2 on Tacrolimus Clearance in Chinese Liver Transplant Recipients-A Population Model Approach.Semantic proximity Read ↗

Safety and Efficacy of Nirmatrelvir/Ritonavir in Advanced Kidney DiseaseSemantic proximity Read ↗

Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients.Semantic proximity Read ↗

Dosing strategy of tacrolimus when co-administered with Wuzhi tablet in renal transplant recipients.Semantic proximity Read ↗

Prediction of tacrolimus and Wuzhi tablet pharmacokinetic interaction magnitude in renal transplant recipients.Semantic proximity Read ↗

Genetic and clinical determinants of mizoribine pharmacokinetics in renal transplant recipients.Semantic proximity Read ↗

Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.Semantic proximity Read ↗

Risk of acute renal failure associated with combined use of SGLT2 inhibitors and potentially nephrotoxic drugs: a pharmacovigilance study based on the FAERS databaseSemantic proximity Read ↗

Risk factors for calcineurin inhibitor nephrotoxicity after renal transplantation: a systematic review and meta-analysis.Semantic proximity Read ↗

Associations of ABCB1, NFKB1, CYP3A, and NR1I2 polymorphisms with cyclosporine trough concentrations in Chinese renal transplant recipients.Semantic proximity Read ↗

Population pharmacokinetic study of cyclosporine in Chinese renal transplant recipients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.